Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OpenBiome Fecal Microbiota Transplantation
- Development stage
- Unknown
- Lead developer
- OpenBiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
OpenBiome Fecal Microbiota Transplantation (FMT) is a microbial therapy consisting of a standardized, filtered suspension of human stool derived from healthy, screened donors. It is designed to restore a diverse and healthy microbial community in patients suffering from intestinal dysbiosis. In the clinical program led by the University of Miami, this FMT product is being investigated for its ability to decolonize or suppress the carriage of multidrug-resistant organisms (MDROs) in the gastrointestinal tract of solid organ transplant recipients. The therapeutic rationale is based on the principle of competitive exclusion, where the introduction of a complex commensal microbiota displaces resistant pathogens and restores colonization resistance, thereby reducing the risk of recurrent MDRO infections in immunocompromised populations.
- Other names
- Fecal Microbiota TransplantationFMTOpenBiome FMTfecal microbiota
Beyond the preview
Go deeper on OpenBiome Fecal Microbiota Transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OpenBiome Fecal Microbiota Transplantation.